GITNUXSOFTWARE REVIEW
Biotechnology & PharmaceuticalsTop 10 Best Biological Process Development Services of 2026
Compare biological process development services by key capabilities and fit, with practical notes for bioprocessing teams evaluating Lonza and others.
How we ranked these tools
Vendors set the topic, but our editors set the inclusion criteria and the evaluation framework before research starts.
Search agents gather the source set and the review record, including transcriptions of video reviews and podcasts.
Framework: Features 40% · Ease 30% · Value 30%
Gitnux may earn a commission through links on this page. This does not influence our reviews. Editorial policy
Lonza is the best pick for mid-to-late biologics programs that need end-to-end process development and tech transfer alignment, because its process characterization deliverables tie upstream performance to downstream impurity control and manufacturing execution, while Evotec fits teams that want coordinated upstream-to-downstream documentation for CMC execution thanks to its decision-linked process development artifacts.
Editor’s top 3 picks
Three quick recommendations before you dive into the full comparison below — each one leads on a different dimension.
Lonza
Process characterization deliverables that map upstream performance to downstream impurity control and manufacturing execution.
Best for: Fits when mid-to-late stage biologics programs need end-to-end process development and tech transfer alignment.
Thermo Fisher Scientific
Editor pickProgram delivery tightly couples analytical method development to process characterization used for comparability and validation dossiers.
Best for: Fits when sponsors need one accountable partner across CMC development, analytics, and transfer deliverables.
Charles River Laboratories
Editor pickProgram execution continuity that links process studies to manufacturing-facing technology transfer planning.
Best for: Fits when development teams need an execution partner that connects studies to CMC-ready tech transfer artifacts.
Comparison Table
Lonza
enterprise_vendorGlobal CDMO offering end-to-end biologics process development from cell line construction through commercial manufacturing.
Process characterization deliverables that map upstream performance to downstream impurity control and manufacturing execution.
Lonza supports biological process development for biologics programs through end-to-end upstream and downstream activities that include media and feed strategy refinement, bioreactor process development, and purification process development. Development outputs are typically organized around product-critical attributes and process parameter control so that later characterization, tech transfer, and validation planning can reuse the same logic. Lonza’s track record is most visible when a program needs tight linkage between process characterization, comparability thinking, and manufacturing-ready documentation.
A key tradeoff is that Lonza’s strongest fit comes when teams can provide stable product definition and timely sample turnaround for iterative experiments, since the work depends on sustained data flow for design of experiments and characterization. Lonza is especially useful for a team moving from early screening into scale-up strategy and process robustness work, where downstream impurity clearance and method development must converge with upstream performance.
- +End-to-end upstream and downstream development linked to tech transfer needs
- +Analytical method development supports strong process characterization for CMC
- +Impurity and viral clearance studies align with purification development planning
- +Scale-up strategy outputs reduce downstream execution ambiguity during transfer
- –Requires disciplined sample and decision cadence to maintain iteration speed
- –Project scope coordination across sites can add administrative overhead
CMC leads
Registration-enabling development package creation
Faster readiness for CMC work
Upstream process teams
Fed-batch scale-up planning
More predictable scale-up outcomes
Show 2 more scenarios
Downstream process teams
Purification and impurity clearance optimization
Cleaner impurity profiles
Develops purification steps and supporting analytics that target impurity reduction and consistent quality.
Biologics program managers
Technology transfer to manufacturing
Lower transfer friction
Packages process characterization findings into documentation teams can execute during transfer.
Best for: Fits when mid-to-late stage biologics programs need end-to-end process development and tech transfer alignment.
Thermo Fisher Scientific
enterprise_vendorCDMO services for biologics process development through the Patheon and Gibco service lines.
Program delivery tightly couples analytical method development to process characterization used for comparability and validation dossiers.
Thermo Fisher Scientific supports cell line development through clone selection work and then carries into upstream and downstream process development with structured study execution. Analytical method development and process analytical technology style monitoring are used to link critical quality attributes and critical process parameters to batch performance. Strong documentation practices show up in manufacturing process description artifacts and batch-record style traceability needed for regulatory handoffs. Thermo Fisher Scientific also fits teams that want a single program thread from development studies through technology transfer planning.
A tradeoff appears in integration and change turnaround time when a program spans multiple sites and requires simultaneous schedule alignment across wet lab, analytical, and documentation streams. The best usage situation is a regulated biologics program that needs comparability assessment after process changes, such as media and feed strategy updates or scale-up studies to define a scale-up strategy. Another good fit is a CMC program that needs impurity clearance and viral clearance experimentation backed by analytical method readiness for release and characterization.
- +End-to-end development coverage from cell line through tech transfer documentation
- +Analytical method development tied to characterization and batch performance
- +Comparability-focused change work supports lifecycle updates
- +Experience spanning impurity clearance and viral clearance studies
- –Cross-site scheduling can slow turnaround on tightly coupled study phases
- –Operational governance requires consistent inputs across lab, analytics, and CMC teams
CMC leads at sponsors
Needs characterization and dossier-ready evidence
Faster documentation assembly
Upstream development teams
Revises feed and media strategy
Clear change justification
Show 2 more scenarios
Downstream process teams
Designs clearance across purification steps
Regulatory-ready clearance package
Impurity clearance and viral clearance experimentation is supported with analytical methods for characterization endpoints.
Regulated manufacturing engineering
Transfers process between facilities
More predictable transfer execution
Technology transfer planning uses process understanding and characterization results to support manufacturing process description.
Best for: Fits when sponsors need one accountable partner across CMC development, analytics, and transfer deliverables.
Charles River Laboratories
enterprise_vendorContract research and manufacturing organization with biologics process development and analytical services.
Program execution continuity that links process studies to manufacturing-facing technology transfer planning.
Charles River Laboratories supports biologics teams through coordinated upstream and downstream process development activities that map to regulatory CMC workflows. The work typically covers experimental planning and iterative characterization tied to critical quality attributes and critical process parameters, with analytical method development feeding interpretability of study results. The strongest fit appears when a program needs both process development experiments and the documentation artifacts that manufacturing teams will reuse for later stages. Integration depth is most visible when internal stakeholders want shared protocols, study traceability, and continuity between development and technology transfer.
A tradeoff is that governance and operational cadence depend on program-specific setup, especially when multiple internal groups feed requirements into experiments and reporting. The provider is a good fit for development-to-scale transitions where the same attributes and assay strategies must remain consistent across bioreactor process development and later tech transfer activities. Usage works well when project leadership already has defined acceptance criteria for assays, comparability expectations, and batch record inputs for downstream execution.
- +Coordinated upstream and downstream workstreams under one execution team
- +Process characterization evidence designed to support manufacturing-facing decisions
- +Assay development support improves interpretability of process experiments
- +Technology transfer planning supports consistency across scale stages
- –Project cadence can require stronger internal coordination than consult-only models
- –Complex governance adds overhead when multiple stakeholders define requirements
CMC and process development leads
Unify studies into tech transfer inputs
Cleaner handoff to manufacturing
Upstream process scientists
Iterate bioreactor conditions for target attributes
Faster attribute convergence
Show 1 more scenario
Downstream engineering teams
Stabilize purification performance across scales
More consistent purification outcomes
Support purification development that maintains process performance for later transfer stages.
Best for: Fits when development teams need an execution partner that connects studies to CMC-ready tech transfer artifacts.
Catalent
enterprise_vendorCDMO offering biologics process development, cell line development, and clinical-to-commercial manufacturing.
Development work is packaged as manufacturing handoff artifacts, linking experiment outcomes to traceable process and analytics documentation.
Catalent delivers biological process development support that spans upstream and downstream work, with an execution model built around CMC-grade documentation and scale transitions. Teams use its development-to-transfer workflows to move from formulation and process characterization toward manufacturing process description packages and batch record-aligned execution.
- +Strong upstream to downstream continuity for integrated CMC transfer packages
- +Clear traceability from development experiments to manufacturing documentation artifacts
- +Analytical method readiness support for comparability and characterization studies
- +Structured governance for technical change tracking across project phases
- –Requires early alignment on scope to keep technology transfer timelines tight
- –Less ideal for fully independent teams needing highly bespoke lab execution control
Best for: Fits when mid-to-large biologics programs need transfer-ready development outputs and documented handoffs to manufacturing.
Evotec
specialistDrug discovery and development partner with biologics process development through Just-Evotec Biologics.
Process development documentation that links experimental decisions to characterization and transfer artifacts for CMC execution.
Evotec delivers biological process development services that cover upstream and downstream work from early feasibility through technology transfer packages for biologics CMC programs. The distinguishing focus is execution across end-to-end process development modules, including cell line development support, bioreactor process development, and purification process development with characterization for comparability.
- +End-to-end process development coverage from upstream to purification
- +Experiment planning that supports decision making during process optimization
- +Documentation packages aligned to technology transfer readiness
- +Characterization emphasis to support comparability and process understanding
- –Integration effort is higher when internal assay methods differ significantly
- –Turnaround depends on interdependencies between process and analytical development
- –Limited visibility into day-to-day workflows without early governance alignment
- –Depth varies by therapeutic modality and facility routing
Best for: Fits when mid-size to large biologics teams need coordinated upstream and downstream development with transfer-ready documentation.
Coriolis Pharma
specialistSpecialist CDMO focused on formulation and process development for biologics and vaccines.
CMC-ready process narratives that connect experimental decisions to downstream controls for tech transfer.
Coriolis Pharma supports biological process development work focused on moving from early upstream definition to downstream strategy decisions for biologics programs. The firm’s distinct value is its blend of hands-on CMC-oriented process development deliverables with regulatory-facing documentation artifacts that map process choices to quality attributes.
- +Process development outputs are formatted for CMC documentation handoff
- +Upstream and downstream strategy decisions stay connected to quality outcomes
- +Experimental planning emphasizes traceability from variables to observations
- +Tech transfer planning artifacts reduce gaps between development and manufacturing
- –Deep automation, API, and data-model tooling are not a visible focus
- –End-to-end clone selection support is limited compared with larger full-stack CDMO networks
Best for: Fits when mid-size biologics teams need CMC-ready process development packages with clear documentation deliverables.
Boehringer Ingelheim BioXcellence
enterprise_vendorBiologics contract manufacturing and process development services under the BioXcellence brand.
Integrated CMC-aligned development deliverables that tie process characterization results to manufacturing documentation.
Boehringer Ingelheim BioXcellence pairs biological process development with strong regulatory CMC orientation, which helps when upstream and downstream work must translate into manufacturing-ready documentation. Core capabilities cover upstream process development, downstream process development, and analytical method development used to support characterization and comparability.
- +Biology-to-Document workflow helps convert experiments into CMC-ready narratives
- +Upstream and downstream development scope supports end-to-end process continuity
- +Analytical method development supports characterization and comparability evidence
- +Process characterization links CQAs and CPPs to experimental design decisions
- –Governance and documentation depth can extend project timelines for small teams
- –Integration automation and API surfaces are not a primary deliverable in engagements
- –Scale-up plans depend on provided scale-down models and internal assumptions
- –Real-time release testing support is limited to defined analytics scopes
Best for: Fits when biologics teams need integrated upstream, downstream, and analytical development aligned to CMC documentation.
Samsung Biologics
enterprise_vendorLarge-capacity biologics CDMO offering cell line and process development through commercial manufacturing.
End-to-end development-to-transfer execution that connects process characterization outputs to manufacturing readiness deliverables.
Samsung Biologics supports biological process development through upstream and downstream process development aimed at CMC continuity from early characterization to tech transfer. Its delivery model is distinct in how it pairs development work with late-stage manufacturing readiness, which is valuable when projects must move quickly toward scale and regulatory documentation.
- +Strong handoff from process characterization into technology transfer execution
- +Broad upstream and downstream scope that supports end-to-end development
- +Development coverage that aligns with impurity clearance and control strategy work
- +Analytical method development support that supports characterization and comparability
- –Integration depth depends on project team coordination around deliverables
- –Automation and API access are not a central feature of the engagement model
- –Governance artifacts like audit logs and RBAC are not typically surfaced
- –Workflows for rapid iteration can slow when documentation reviews dominate
Best for: Fits when biologics programs need development tightly coupled to scale-up and transfer readiness.
WuXi Biologics
enterprise_vendorOpen-access biologics platform providing cell line, process, and manufacturing development services.
Program team delivery model that keeps upstream and downstream development aligned to manufacturing transfer needs.
WuXi Biologics delivers biological process development services that connect upstream and downstream work into CMC-relevant process development deliverables for biologics programs. Strength shows in supporting end-to-end development activities that feed technology transfer, characterization planning, and manufacturing readiness workflows.
- +End-to-end upstream and downstream process development for CMC continuity
- +Structured experimental workflows for process understanding and scale decisions
- +Experience-driven scale-up strategy support for commercial trajectory planning
- +Clear handoff artifacts that support technology transfer planning
- –Coordination overhead increases for highly fragmented work package boundaries
- –Less focus on single-method niche work when programs demand very specific analytics
Best for: Fits when a biologics team needs integrated upstream and downstream development toward technology transfer.
KBI Biopharma
specialistCDMO providing process development and manufacturing for protein-based biologics.
CMC-focused manufacturing process description delivered in the same development flow as process characterization outputs, improving transfer continuity.
KBI Biopharma supports biologics teams with hands-on biological process development that spans cell line development through upstream and downstream process development. The service package emphasizes experimentally grounded process characterization and CMC-ready manufacturing process documentation for scale-up strategy and technology transfer.
- +End-to-end upstream to downstream development coverage for biologics programs
- +Process characterization work supports later scale-up strategy decisions
- +CMC-facing manufacturing process description is produced for transfer activities
- +Project teams coordinate experiments to reduce rework across development phases
- –Limited evidence of API-driven automation for data and workflow integration
- –Analytical method development depth can vary by program scope and chemistry
- –Governance tooling is not a primary feature compared with vendor-managed execution
- –Clone selection and fed-batch planning coverage may be thin for specialized needs
Best for: Fits when biologics teams need an experienced development partner to drive CMC-ready upstream and downstream work.
Conclusion
After evaluating 10 biological process development, Lonza stands out as our overall top pick — it scored highest across our combined criteria of features, ease of use, and value, which is why it sits at #1 in the rankings above.
Use the comparison table and detailed reviews above to validate the fit against your own requirements before committing to a tool.
Frequently Asked Questions About Biological Process Development
Which providers most often deliver development-to-transfer artifacts for biologics manufacturing?
How does onboarding usually work when upstream and downstream workstreams must stay aligned?
When should teams request process characterization deliverables tied to critical quality attributes and critical process parameters?
What breaks if a development engagement stops short of manufacturing-facing documentation?
How do these providers handle integration of assay strategy with process development data for comparability?
Which providers show stronger support for impurity clearance strategy across upstream and downstream development?
How do teams manage change control when process updates occur during scale transitions?
What data migration approach is typically required when a sponsor moves development records into existing internal systems?
Where does security and access control most often surface during supplier collaboration?
Tools reviewed
Primary sources checked during evaluation.
Referenced in the comparison table and product reviews above.
How to Choose the Right Biological Process Development
We separate tools in biological process development by how well they manage experimental-to-process learning: the biggest gap is often reproducible workflow support through each study, shown by design of experiments automation and audit-ready run details. Then we look at whether throughput is practical when you iterate conditions and compare results without manual spreadsheet glue.
Run traceability across experiments
Why it matters
Run traceability across experiments matters in biological process development because decisions depend on what changed, when, and which inputs produced the outcome. Without it, it’s hard to learn from iterations or reproduce a prior state.
How to check
Start a small workflow from a sample experiment and check whether each step captures inputs, versions, and outputs. Ask the demo team to export a single run summary that you can use to compare two similar runs.
Design of experiments automation
Why it matters
Design of experiments automation reduces error when you explore multiple factors at once, which is common in biological process development. It also keeps factor definitions consistent across batches of studies.
How to check
In the UI, create a study that varies at least two factors and review whether the tool generates the proposed runs and tracks assignments. Request to see how it records factor levels and ties them back to outcomes.
Iteration support across scale studies
Why it matters
Biological process development often needs scale iteration, and the iteration support across scale studies helps you preserve what was learned while you move to a new regime. The wrong abstraction forces you to rebuild comparisons from scratch.
How to check
Pick two projects representing different study conditions and see whether the tool links results to shared experimental definitions. Ask whether you can compare outputs side-by-side while keeping the design assumptions visible.
Structured storage for process inputs
Why it matters
Structured storage for process inputs matters because upstream and downstream work depend on many measured and nominal values. A weak data model turns key fields into free-text, which breaks reliable comparison and reporting.
How to check
Load a sample dataset and confirm you can map process inputs to fields rather than raw notes. Then filter or query by a specific input value and verify the results update instantly.
Analytical results workflow alignment
Why it matters
Analytical results workflow alignment matters because biological process development depends on consistent handling of measurement outputs tied to the study run. When analysis is bolted on, you lose the connection between experiments and interpretations.
How to check
In a demo, import or attach analytical measurements to an experiment run. Check whether the tool links measurement files or summaries to the exact run and supports basic review states for each result set.
Automation via API and import templates
Why it matters
Automation via API and import templates matters because biological process development teams often need repeatable provisioning of new studies and regular imports from lab systems. If the surface is thin, users fall back to manual copying.
How to check
Ask what endpoints or integration hooks exist for creating studies and ingesting results, and review the sample payloads in the documentation. In the UI, use import templates with a provided example file and verify the fields land correctly.
Red flags
- Run history collapses into free-text notes
- Design of experiments supports factors but can’t track levels to outcomes
- Analytical results aren’t reliably tied to the originating run
Fit by situation
- If our team runs many factor studies, prioritize design of experiments automation.
- If we need to revisit prior decisions months later, prioritize run traceability across experiments.
- If lab outputs arrive frequently from different formats, prioritize automation via API and import templates.
Funding and competing interests
This study was co-funded by several of the vendors assessed in it. No single vendor funded it. Funders could propose the market studied.
They had no role in selecting vendors, setting or weighting criteria, analysing data or drawing conclusions, and they received the same factual-accuracy check as every other vendor assessed.
Market definition, inclusion rules and criteria weights were fixed by an editor before research began and did not change afterwards. Editorial process →
- Service review · 2026 · Biotechnology PharmaceuticalsBioinformatics
- Service review · 2026 · Biotechnology PharmaceuticalsBioengineering
- Service review · 2026 · Biotechnology PharmaceuticalsBioanalytics
- Service review · 2026 · Biotechnology PharmaceuticalsBioanalytical
- Review · 2026 · Biotechnology PharmaceuticalsBiological Software
Keep exploring
Comparing two specific tools?
Software Alternatives
See head-to-head software comparisons with feature breakdowns, pricing, and our recommendation for each use case.
Explore software alternatives→In this category
Biotechnology & Pharmaceuticals alternatives
See side-by-side comparisons of biotechnology & pharmaceuticals tools and pick the right one for your stack.
Compare biotechnology & pharmaceuticals tools→